Titan PharmaceuticalsTTNP
13F holders, Q3 2025 (September 30)18holders −2
3new positions
5sold out
$4.79avg. 13F price*
At the end of Q3 2025, 18 institutions reported holding Titan Pharmaceuticals Inc. (TTNP) in their 13F filings, down 2 from Q2 2025. 3 opened new positions and 5 sold out. The largest holders were DRW Securities, LLC ($102K), UBS Group AG ($2K) and Tower Research Capital LLC (TRC) ($2K).
- Company
- Titan Pharmaceuticals Inc.
- CUSIP
- 888314705
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2025 → Q3 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $104K |
| Exits | 5 | $143K |
All 13F filers, Q2 2025 → Q3 2025: 21,738 shares bought and 37,061 shares sold, net −15,323 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 18 holders
| DRW Securities, LLC | 0.01% | New | 21,267 | $102K |
| UBS Group AG | 0.00% | Reduce -86.0% | 480 | $2K |
| Tower Research Capital LLC (TRC) | 0.00% | New | 469 | $2K |
| CoreCap Advisors, LLC | 0.00% | No change | 88 | $422 |
| Bank of America Corp. | 0.00% | Add +5.6% | 19 | $91 |
| Group One Trading LLC | 0.00% | No change | 12 | $58 |
| Osaic Holdings, Inc. | 0.00% | No change | 10 | $35 |
| BlackRock, Inc. | 0.00% | No change | 6 | $29 |
| Morgan Stanley | 0.00% | No change | 2 | $10 |
| Global Wealth Strategies & Associates | 0.00% | No change | 2 | $10 |
| Wells Fargo & Company | 0.00% | No change | 1 | $5 |
| Caldwell Sutter Capital, Inc. | 0.00% | No change | 1 | $5 |
| St Germain D J Co. Inc. | 0.00% | No change | 1 | $5 |
| Westside Investment Management, Inc. | 0.00% | No change | 1 | $5 |
| SBI Securities Co., Ltd. | 0.00% | No change | 1 | $5 |
| Nemes Rush Group LLC | 0.00% | No change | 1 | $5 |
| Ransom Advisory, Ltd | 0.00% | No change | 1 | $5 |
| Cwm, LLC | 0.00% | New | 1 | $0 |
"% of holder's portfolio" is TTNP's weight in each manager's 13F, not the share of Titan Pharmaceuticals Inc. the manager owns.